← FDA DRUG APPROVALS

FDA ANDA · ANDA204152

OMEPRAZOLE MAGNESIUM

Sponsor: PERRIGO R AND D

APPLICATION
ANDA204152
TYPE
ANDA
ORIGINAL APPROVAL
2015-07-30
LATEST ACTION
2026-06-25
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

OMEPRAZOLE MAGNESIUMDiscontinued
OMEPRAZOLE MAGNESIUM EQ 20MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2026-06-25Labeling · Supplement 10 · standardAP
2026-06-25Labeling · Supplement 8 · standardAP
2026-06-25Labeling · Supplement 6 · standardAP
2018-05-04Manufacturing (CMC) · Supplement 5AP
2016-04-28Labeling · Supplement 1 · standardAP
2015-07-30UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →